跳至主要内容
临床试验/NCT04855526
NCT04855526尚未招募早期 1 期

Effects of Marijuana on Memory-Related Neurochemistry and Neural Response

Hartford Hospital0 个研究点目标入组 9 人开始时间: 2025年12月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
早期 1 期
状态
尚未招募
入组人数
9
主要终点
fMRI response

研究概览

简要总结

Memory deficits are one of the most consistently observed cognitive effects of marijuana use. There is evidence that some decrements attributable to the primary psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), may be attenuated by cannabidiol (CBD). This study will help us learn more about the relationship between THC and CBD consumption with memory processes. A combination of MRI and neuropsychological tests (which are computer and paper/pencil tasks) will be used to measure the neurocognitive and behavioral impacts of THC and CBD use.

详细描述

With increased legalization and medicalization of marijuana (MJ), there is an urgent need to understand the acute effects of use. One of the most consistently observed cognitive outcomes associated with MJ use is memory dysfunction, which may have a substantial impact on daily life in individuals using MJ for recreational or medicinal purposes. Notably, there are numerous preparations of MJ with varying proportions of cannabinoids, which may differ in behavioral and cognitive effects. For instance, there is emerging evidence that acute administration of delta-9-tetrahydrocannabinol (THC), the main psychoactive constituent of MJ, hinders memory and reduces prefrontal and hippocampal functional magnetic resonance imaging (fMRI) activation, but cannabidiol (CBD) may mitigate some of these impairments. Given the role of glutamate in learning and memory, the investigators suggest that these effects may be subserved, in part, by glutamatergic mechanisms. The investigators will use magnetic resonance spectroscopy (MRS) to non-invasively measure glutamate in order to explore the neurochemical underpinnings of memory-related fMRI response changes following acute administration of THC and CBD in a randomized, double-blind, placebo-controlled, cross-over design. A total of 9 healthy participants ages 18-40 will be enrolled. Participants will first undergo one screening visit (~4 hours), comprising informed consent, assessment of health history, psychiatric diagnoses, cognitive function, and substance use history, and a structural MRI session. This will be followed by 3 separate MJ dose visits (~4 hours each), at which participants will complete neuroimaging after administration of one of 3 preparations of vaporized MJ in a randomized, counterbalanced, double-blinded fashion: 1) high THC and no CBD (THC), 2) high THC and high CBD (THC+CBD), and 3) no THC and no CBD (placebo MJ). As in the investigator's ongoing studies, bulk MJ plant material will be provided by the National Institute on Drug Abuse. MJ dose visits will comprise MJ administration, blood collection, MRS/fMRI scan, subjective reports, and a brief cognitive assessment.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Right-handed
  • Prior MJ users (has used MJ at least once in the past year, but no more than 1x/month in the past 12 months)
  • Medically healthy (as determined by medical history and treatment)
  • Adequate comprehension of English in order to complete study materials
  • Acceptable birth control method for women (i.e., no copper IUD or any device that is not MRI safe)

排除标准

  • Participant currently uses psychoactive medications or substances
  • Psychiatric diagnoses (determined by DSM-V)
  • Participant heavily or regularly uses MJ (more than 1x/month in the past year)
  • Current or past substance dependence (including MJ)
  • Positive urine toxicology screens
  • Positive pregnancy screens
  • MRI contraindications (e.g., heart pacemaker)

研究组 & 干预措施

Occasional Users - High THC and High CBD Dose

Experimental

People who smoke marijuana occasionally will be given a dose of high THC high CBD marijuana at the study visit

干预措施: High THC/High CBD Marihuana (Drug)

Occasional Users - High THC and No CBD Dose

Experimental

People who smoke marijuana occasionally will be given a dose of high THC and no CBD marijuana at the study visit

干预措施: High THC/No CBD Marihuana (Drug)

Occasional Users - No THC and No CBD Dose

Experimental

People who smoke marijuana occasionally will be given a dose of marijuana that contains no THC or CBD

干预措施: No THC/No CBD Marihuana (Drug)

结局指标

主要结局

fMRI response

时间窗: approximately 1 hour following drug administration

Blood oxygen level dependent functional magnetic resonance imaging (fMRI) response during the relational and item specific encoding task. fMRI response will be evaluated during the encoding phase (relational vs. item encoding), item recognition phase (hits vs. misses for item-specific encoding, and hits vs. misses for relational encoding), and associative recognition phase (hits vs. misses).

Glutamate

时间窗: approximately 1 hour following drug administration

Magnetic resonance spectroscopy (MRS)-acquired glutamate containing compounds (Glx).

次要结局

  • Blood THC and CBD concentration testing(Immediately after drug administration (~0.25 hours after drug administration))
  • Subjective effects on drug effects questionnaire(Post drug administration at: 0.00 hours (immediately after); 1.0 hours; 2.0 hours; 3.0 hours)
  • HVLT-R performance(Approximately 2.50 hours after drug administration)
  • Performance on CHARLIE cognitive task(Approximately 3.00 hours after drug administration)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Godfrey Pearlson

Founding Director Olin Neuropsychiatry Research Center; Professor Yale University

Hartford Hospital

相似试验